Abstract
The Korean Society of Hypertension (KSH)- Hypertension Epidemiology Research Working Group has analyzed national big data to provide an overview of the magnitude and management status of hypertension and their recent trends. The analyses included data for Korean adults aged 20 years or older of the 1998–2020 Korea National Health and Nutrition Examination Survey and the 2002–2020 National Health Insurance Big Data. As of year 2020, the population average of systolic/diastolic blood pressure was 118/76 mmHg in Korean adults aged 20 years or older showing little change in the recent decade. It is estimated that 29% of the adult population aged 20 or older (34% of adults aged 30 or older) have hypertension. The estimated number of people with hypertension was 7.2 million for men and 5.5 million for women. Among them, 2.0 million men and 3.0 million women are aged 65 or older. The number of people diagnosed with hypertension increased from 3.0 million in 2002 to 10.5 million in 2020. During the same period, the number of people using antihypertensive medication increased from 2.5 million to 9.9 million, and the number of people adherent to treatment increased from 0.6 million to 7.4 million. Among antihypertensive prescriptions, 40% of the patients received monotherapy, 44% received dual therapy, and 16% received triple or more therapy. The most commonly prescribed antihypertensive medication was angiotensin receptor blockers (ARB), followed by calcium channel blockers (CCB) and diuretics. Among the adult Korean population aged 20–64, there are 5.9 million controlled hypertension, 3.9 million treated-but-uncontrolled hypertension, 3.2 million diagnosed-but-untreated hypertension, and 1.5 million undiagnosed hypertension. Among the Korean elderly population aged 65 or older, there are 3.6 million have controlled hypertension, 1.5 million treated-but-uncontrolled hypertension, 0.8 million diagnosed-but-untreated hypertension, and 0.4 million undiagnosed hypertension.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
